Combining clinical results with immunological findings, possibly coupled with the discovery of biomarkers predictive for response, will allow us to determine the best approaches to immunotherapy in AML, also in those high-risk scenarios with TP53 mutations. Here, TP53 is linked to acute myeloid leukemia.